Combination drug trial for relapsed brain lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL), confirmed by biopsy.
- Your cancer has come back or stopped responding to previous treatment with high-dose methotrexate and/or BTK inhibitors.
- You are between 18 and 75 years old and expected to survive at least 3 months.
- Your blood cell counts, kidney function, and liver function meet minimum safe levels for the study drugs.
- You are not pregnant, breastfeeding, or unwilling to use effective birth control if you could become pregnant.
- You do not have active infections, HIV, autoimmune diseases, or severe neurological conditions like epilepsy or dementia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs — high-dose methotrexate, thiotepa, and zanubrutinib — for people newly diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
Hear when a new Primary Central Nervous System Lymphoma (PCNSL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.